4D MOLECULAR THERAPEUTICS IN

CEO David Kirn sells 26,842 shares of 4D Molecular Therapeutics under a rule‑based plan, showing disciplined insider activity without warning of distress.

4D Molecular’s CEO sells 12,415 shares under a 10b‑5‑1 plan—stable prices, controlled liquidity, and no market impact, while clinical milestones drive future value.

CEO David Kirn’s 10(b)(5) sales at 4D Molecular reveal strategic liquidity while still backing the biotech’s clinical pipeline—what it means for investors.

4D Molecular’s insider buying & option sales reveal CEO Bizily Scott’s confidence in the company’s clinical pipeline, hinting at future upside and a strategic, compliant approach to trading under a 10(b)(5) plan.

CEO sale of 114,746 4D Molecular Therapeutics shares shows disciplined liquidity management while the company’s gene‑therapy pipeline, strong safety data and FDA approvals signal solid growth prospects for investors and clinicians.

4D Molecular Therapeutics insider sale: CEO David Kirn sells 1,922 shares via a 10(b)(5)(1) plan at $10.02—showing confidence while keeping long‑term stake.